From China’s Mountains to the World’s Mountains: KAILAS Deepens Its Global Expansion Strategy
7.9.2026 12:58:00 EEST | Business Wire | Press release
In late August 2026, KAILAS FUGA, the trail-running brand of KAILAS, a China-based professional outdoor brand, officially opened its first European store in Chamonix, France. As KAILAS’s first directly operated international store, the new location not only gives the brand a more direct presence in the European market, but also marks a new stage in its global expansion — moving from years of investment in products, events, athletes and international channels toward more localized operations and deeper brand development.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260906651659/en/
KAILAS First European Store in Chamonix
Founded in 2003, KAILAS is one of the world’s three leading full-category climbing brands. Over more than two decades, the company has built its professional capabilities through product development, professional athletes, events and testing in real mountain environments. From mountaineering, rock climbing and ice climbing to trail running, KAILAS has progressively developed a product portfolio serving multiple mountain sports. This sustained commitment to professional excellence forms the foundation for KAILAS to enter international markets and compete alongside established global outdoor brands. As of the end of 2024, KAILAS had more than 300 sales outlets overseas, 107 elite athletes worldwide, and organized or co-organized more than 200 events annually. These investments have not been made to capitalize on any single market trend, but represent a long-term effort built steadily over many years.
For KAILAS, choosing Chamonix was not simply a decision to open an overseas store. Chamonix is a major destination for outdoor and trail-running activities, as well as a core gathering point for professional runners, outdoor brands and communities from around the world. During the 2026 UTMB® World Series Finals, elite trail-running athletes from across the globe will once again converge here. Establishing its first directly operated international store at this important center of global mountain culture is a clear expression of KAILAS’s professional positioning and long-term international strategy.
The store is not positioned simply as a traditional retail space, but as a FUGA Basecamp connecting athletes, runners and the local outdoor community. Around the store opening, KAILAS is bringing together product experiences, athlete exchanges and trail-running activities, with more than 80 athletes from the FUGA Team and FUGA Mountain Club participating in UTMB®, TDS®, CCC®, OCC® and ETC® events. At the same time, the new FUGA EX PRO G is making its debut in Chamonix, bringing product development, professional athletes and real mountain environments into direct connection.
From bringing products into overseas markets, to building international athlete and event networks, and now to establishing its own directly operated international presence, KAILAS is moving from taking products overseas to building a deeper presence in the global mountain sports ecosystem. For KAILAS, competing alongside leading international brands is a sustained test of professional capability and long-term commitment. Establishing a presence in Chamonix means entering a more mature, highly professional and more demanding market, where products, athletes and real-world performance can be tested over the long term. Choosing Chamonix is, at its core, a continuation of KAILAS’s longstanding professional logic — not going overseas simply for the sake of going overseas, but going where professional sport truly happens.
Looking ahead, KAILAS will continue to build on product expertise, connect through athletes and events, and validate its capabilities in real mountain environments, deepening its long-term relationships with mountain sports communities around the world. The FUGA store in Chamonix is therefore more than a new retail location: it is a tangible result of years of professional investment in Europe and a new marker of KAILAS’s commitment to doing the difficult and meaningful work that takes time.
About KAILAS
Founded in 2003, KAILAS has grown into one of the world's leading climbing and mountain sports brands, committed to advancing mountaineering and exploration while providing high-performance outdoor equipment for athletes and dedicated enthusiasts.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260906651659/en/
Contacts
KAILAS PR Team
pr@kailas.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 14:30:00 EEST | Press release
Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom